- $150.99bn
- $199.12bn
- $33.42bn
- 90
- 35
- 75
- 74
Annual cashflow statement for Amgen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 7,264 | 5,893 | 6,552 | 6,717 | 4,090 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 135 | 1,617 | 1,683 | -560 | 671 |
Unusual Items | |||||
Purchased R&D | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -216 | -1,194 | -733 | -484 | 2,365 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 10,497 | 9,261 | 9,721 | 8,471 | 11,490 |
Capital Expenditures | -608 | -880 | -936 | -1,112 | -1,096 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -4,793 | 1,613 | -5,108 | -25,092 | 50 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -5,401 | 733 | -6,044 | -26,204 | -1,046 |
Financing Cash Flow Items | -90 | -78 | -103 | -72 | -124 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -4,867 | -8,271 | -4,037 | 21,048 | -9,415 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 229 | 1,723 | -360 | 3,315 | 1,029 |